Radiopharm Theranostics (RADX) Current Deferred Revenue (2025)

Radiopharm Theranostics (RADX) reported Current Deferred Revenue of $11019.0 for Q2 2025.

Radiopharm Theranostics (RADX) Current Deferred Revenue (2025) Analysis & Trends

Radiopharm Theranostics (RADX) has 1 years of Current Deferred Revenue data on file, last reported at $11019.0 in Q2 2025.

Current Deferred Revenue for Q2 2025 came in at $11019.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $11019.0 (changed N/A YoY), and the FY2025 annual result was $11019.0, changed N/A from the prior year.
Current Deferred Revenue was little changed at $11019.0 in Q2 2025 per RADX's latest filing.
Over five years, Current Deferred Revenue peaked at $11019.0 in Q2 2025 and troughed at $11019.0 in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Radiopharm Theranostics	5.82 Bn	5.81 Bn	-

Historic Data

Download Data

Date	Value
Jun 30, 2025	11,018.98